New Journey(002219) 湘财证券·2024-07-10 09:01Company Overview - The company has been engaged in the R&D, production, and sales of pharmaceutical products for over 20 years, with the "Duyiwei" brand being a well-known trademark in China [1] - The company has developed a product line centered around the "Duyiwei" series, including 82 varieties, 46 of which are listed in the National Pharmacopoeia, and 8 are exclusive production varieties [1] - In 2023, the pharmaceutical manufacturing business achieved revenue of 774 million yuan, a year-on-year increase of 51.2% [1] Financial Performance - The company achieved total revenue of 3.59 billion yuan in 2023, a year-on-year increase of 13.59%, with the medical services segment contributing 2.816 billion yuan (up 6.32%) and the pharmaceutical segment contributing 774 million yuan (up 51.22%) [12] - Net profit for 2023 was 38.9121 million yuan, with net profit attributable to the parent company being 30.7766 million yuan [12] - The company's asset-liability ratio at the end of 2023 was 63.25%, a decrease of 5.54 percentage points from the beginning of the year, indicating continuous improvement in capital structure [12] Business Segments Medical Services - The company operates 11 hospitals, including 3 tertiary and 7 secondary or above comprehensive or specialized hospitals, with nearly 10,000 beds [52] - In 2023, the medical services segment achieved revenue of 2.816 billion yuan, a year-on-year increase of 6.3%, with bed utilization rate increasing from 88% in 2022 to 91% in 2023 [52] - Key hospitals include Lankao First Hospital, Wafangdian Third Hospital, Xuyi County Hospital of Traditional Chinese Medicine, Chongzhou Second Hospital, and Siyang Hospital [52] Pharmaceutical Manufacturing - The company has leveraged the blood-activating and stasis-removing properties of "Duyiwei" to develop a product line for oral care, entering the fast-moving consumer goods market [1] - The pharmaceutical segment achieved revenue of 774 million yuan in 2023, a year-on-year increase of 51.2% [1] Future Outlook - The company is expected to achieve revenues of 4.118 billion yuan, 4.646 billion yuan, and 5.209 billion yuan in 2024, 2025, and 2026, respectively, with net profits attributable to the parent company of 144 million yuan, 217 million yuan, and 292 million yuan [1][9] - EPS is projected to be 0.04 yuan, 0.06 yuan, and 0.09 yuan for 2024, 2025, and 2026, respectively [1][9] - The company plans to expand bed capacity in existing hospitals and potentially inject high-quality medical assets from its parent company into the listed entity [60] Investment Rating - The company is rated as "Overweight" in its first coverage, with expected outperformance relative to the market benchmark index by 5% to 15% over the next 6-12 months [1][40]